In-vitro drug release from biodegradable matrices : analysis, modeling and application in vascular stents

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Materials Science, Engineering

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Biodegradable stents.

  2008cited by this paper
• Paclitaxel release from single and double-layered poly(DL-lactide-co-glycolide)/poly(L-lactide) film for biodegradable coronary stent application.

  2008cited by this paper
• Adjustable paclitaxel release kinetics and its efficacy to inhibit smooth muscle cells proliferation.

  2008cited by this paper
• Desorption-limited mechanism of release from polymer nanofibers.

  2008cited by this paper
• Release profiles in drug-eluting stents: issues and uncertainties.

  2007cited by this paper
• Collapse pressures of bilayered biodegradable stents.

  2006cited by this paper
• Biodegradable stents with elastic memory.

  2006cited by this paper
• Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory.

  2006influential reference
• Treatment options in the management of ovarian cancer

  2005cited by this paper
• Molecular Basis of Restenosis and Drug-Eluting Stents

  2005cited by this paper
• Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel.

  2004cited by this paper
• Effect of plasticization on heparin release from biodegradable matrices.

  2004cited by this paper
• Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial

  2004influential reference
• Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.

  2004cited by this paper
• The Effects of Paclitaxel on the Three Phases of Restenosis: Smooth Muscle Cell Proliferation, Migration, and Matrix Formation: An In Vitro Study

  2004cited by this paper
• Collapse pressures of biodegradable stents.

  2003cited by this paper
• PLGA/TPGS Nanoparticles for Controlled Release of Paclitaxel: Effects of the Emulsifier and Drug Loading Ratio

  2003cited by this paper
• Drug-Eluting Stents : Part II

  2003cited by this paper
• Drug‐Eluting Stents: Cost Versus Clinical Benefit

  2003cited by this paper
• Drug-eluting stents in vascular intervention.

  2003cited by this paper
• Drug‐eluting stents for the prevention of restenosis: In quest for the holy grail

  2002cited by this paper
• Inflammation and Restenosis in the Stent Era

  2002cited by this paper
• PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release.

  2002influential reference
• Synthesis and evaluation of water-soluble paclitaxel prodrugs.

  2002cited by this paper
• Stent‐based antirestenotic coatings (sirolimus/paclitaxel)

  2002influential reference
• Bench to bedside: the development of rapamycin and its application to stent restenosis.

  2001cited by this paper
• Mathematical modeling of bioerodible, polymeric drug delivery systems.

  2001cited by this paper
• Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up.

  2001influential reference
• Intravascular ultrasound: novel pathophysiological insights and current clinical applications.

  2001cited by this paper
• Rapamycin: clinical results and future opportunities.

  2001cited by this paper
• Regional drug delivery with radiation for the treatment of Ewing's sarcoma. In vitro development of a taxol release system.

  2001cited by this paper
• Long-term (> or =8 years) outcome after Palmaz-Schatz stent implantation.

  2001cited by this paper
• Drug-eluting stents: flashy future or flash-in-the-pan?

  2001cited by this paper
• Novel Drug-Delivery Stent: Intravascular Ultrasound Observations From the First Human Experience With the QP2-Eluting Polymer Stent System

  2001influential reference
• The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured?

  2001influential reference
• Biodegradable Polymers as Drug Carrier Systems

  2001influential reference
• Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.

  2000cited by this paper
• Biodegradable stents : "fulfilling the mission and stepping away".

  2000cited by this paper
• Drug delivery systems for the treatment of restenosis.

  2000cited by this paper
• Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators.

  2000influential reference
• Release of mifepristone from biodegradable matrices: experimental and theoretical evaluations.

  2000influential reference
• Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty.

  1999cited by this paper
• Biodegradable polymers : polyesters

  1999influential reference
• Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin).

  1998cited by this paper
• Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry.

  1998cited by this paper
• Biocompatibility aspects of new stent technology.

  1998cited by this paper
• Inhibition of platelet deposition with local delivery of heparin using a double balloon catheter.

  1997influential reference
• Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.

  1997cited by this paper
• Molecular analysis of drug delivery systems controlled by dissolution of the polymer carrier.

  1997cited by this paper
• A theoretical model of erosion and macromolecular drug release from biodegrading microspheres.

  1997influential reference
• Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.

  1996cited by this paper
• Three-year clinical follow-up after Palmaz-Schatz stenting.

  1996cited by this paper
• Paclitaxel partitioning into lipid bilayers.

  1996cited by this paper
• New devices in interventional cardiology: present and future.

  1996cited by this paper
• Side Effects of Rapamycin in the Rat

  1995cited by this paper
• Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel-coated balloon.

  1995influential reference
• Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.

  1995cited by this paper
• Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

  1995cited by this paper
• On liquid diffusion

  1995cited by this paper
• Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target?

  1995cited by this paper
• TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.

  1995cited by this paper
• Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.

  1995cited by this paper
• A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

  1994cited by this paper
• A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

  1994cited by this paper
• Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

  1993cited by this paper
• Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty.

  1993cited by this paper
• Degradable polymers for site-specific drug delivery

  1992cited by this paper
• A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression

  1992cited by this paper
• Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity.

  1992cited by this paper
• Stenting of coronary arteries: has a modern Pandora's box been opened?

  1991cited by this paper
• Drug Delivery Systems 5B. Oral Drug Delivery

  1991influential reference
• Thrombin and other potential mechanisms underlying restenosis.

  1991cited by this paper
• Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat.

  1991cited by this paper
• Mechanical features of the duke biodegradable intravascular stent

  1991cited by this paper
• Bioerodible polymers for delivery of macromolecules

  1990cited by this paper
• Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia

  1989cited by this paper
• Polymeric controlled drug delivery

  1988cited by this paper
• Interventional cardiac catheterization at Duke Medical Center.

  1988cited by this paper
• Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.

  1987cited by this paper
• Controlled release of bioactive agents

  1984cited by this paper
• Biomaterials for drug delivery systems.

  1983cited by this paper
• Elementary osmotic pump for indomethacin.

  1983cited by this paper
• Mechanism of the anticoagulant action of heparin

  1982cited by this paper
• Results from coronary angioplasty and implications for the future.

  1982cited by this paper
• Hydrolytic degradation of polyglycolic acid: Tensile strength and crystallinity study

  1981cited by this paper
• Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins.

  1981cited by this paper
• Heparin and protease inhibition. I. Heparin complexes with thrombin, plasmin, and trypsin.

  1981cited by this paper
• Aliphatic polyesters. I. The degradation of poly(ϵ‐caprolactone) in vivo

  1981cited by this paper
• Diffusional release of a solute from a polymeric matrix — approximate analytical solutions

  1980cited by this paper
• Colorimetric method for the assay of heparin content in immobilized heparin preparations.

  1980cited by this paper
• Promotion of microtubule assembly in vitro by taxol

  1979cited by this paper
• Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.

  1979cited by this paper
• Swelling‐controlled, constant rate delivery systems

  1978cited by this paper
• Diffusional release of a solute from a polymer matrix

  1976cited by this paper
• MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES.

  1963cited by this paper
• Rate of release of medicaments from ointment bases containing drugs in suspension.

  1961cited by this paper

• PEGylated calcium phosphate nano-carriers

  2011cites this paper